I Built His Empire With My Research

Chapter 4 The Hidden Collapse

The first cracks in their stolen edifice appeared not as a sudden quake, but as a series of hairline fractures, visible only to someone who knew exactly where to look. At Apex, I had access to Med-Track, a powerful real-time data aggregator that monitored clinical trials worldwide. It was an ocean of information, and I was hunting for a single, specific shark.

Three months after their trial began, I found it.

It wasn't in the official weekly reports Liam’s team filed with the FDA, which were suspiciously pristine. The data there showed stable patient vitals and manageable, expected side effects. It was in the ancillary data streams—the raw, uncurated feeds from the hospital’s internal systems that Med-Track scraped and archived.

“Anya, can you come see this?” I called, my voice low.

Dr. Sharma was at my side in seconds, her sharp eyes fixed on my screen. I had isolated the data for three patients from the Genesis-X trial—Patient 07, Patient 11, and Patient 19.

“Look at their liver enzyme panels,” I said, highlighting a graph. “ALT and AST levels. For the first four weeks, they’re elevated but within the acceptable range for this kind of aggressive therapy. But look at week five. And six.”

The lines on the graph, once gently sloping, suddenly spiked into jagged peaks, climbing far into the red zone labeled ‘Severe Hepatotoxicity.’

“And here,” I said, pulling up another window. “Serum creatinine. A clear indicator of kidney function.”

The story was the same. A slow, insidious rise, then a sudden, catastrophic failure.

“They’re hiding this,” Anya breathed, her voice a mixture of ice and fury. “They’re cherry-picking the data for their FDA submissions, reporting only the figures from the first month of treatment and attributing later complications to the patients’ glioblastoma.”

“Worse,” I said, clicking one final time. I brought up the hospital admission records for Patient 07. He had been readmitted two days ago for acute liver failure. His official cause of death, filed just this morning, was listed as ‘complications from metastatic brain cancer.’

“It’s the perfect crime,” Anya murmured, staring at the screen. “They’re testing a poison on terminally ill patients, and when the poison does its work, they’re letting the disease take the blame.”

She straightened up, her corporate composure a mask over a scientist’s outrage. “We have to report this. An anonymous tip to the FDA’s Office of Scientific Investigations. We can shut them down before anyone else dies.”

I held up a hand. “Not yet.”

She looked at me, her brow furrowed. “Elara, people are dying.”

“And reporting them now will trigger an internal investigation,” I countered, my voice calm and cold. “Vance will pull strings. He’ll bury it in committees and reviews. They’ll pause the trial, sacrifice a junior researcher, and claim a protocol error. They’ll survive. The work will be tainted, but their careers will go on. That’s not enough.”

My gaze went to the calendar on the wall. The International Neuro-Oncology Summit in Geneva was just six weeks away. Liam’s name was already on the preliminary schedule as a keynote speaker.

“They’re rushing,” I said. “They’re cutting corners and falsifying data for a reason. They’re not just aiming for a publication; they’re aiming for the biggest stage in our field. They want to be crowned in Geneva.”

Anya’s sharp mind immediately saw my logic. “You want to let them walk right into the spotlight before you expose them.”

“You don’t expose a fraud when they’re hiding in the shadows,” I replied. “You wait until they’re on the world’s biggest stage, bathed in a million watts of light. You let them fly as high as they possibly can.”

Anya was silent for a long moment, the gears turning behind her eyes. Finally, she gave a slow, deliberate nod. “Alright, Dr. Vance. We do it your way. But you will monitor this every single hour. The second another patient enters critical condition, we act. Agreed?”

“Agreed,” I said.

In the hallowed, wood-paneled office of Professor Vance, the air was thick with the scent of old books and new panic. The latest report from the clinical trial lay on his mahogany desk like a death sentence.

Liam paced in front of the fireplace, his hands running through his hair. The confident, charming visionary was gone, replaced by a cornered animal.

“A second death, Julian,” he said, his voice strained. “Patient 11. Same as the first—complete liver shutdown. The review board is starting to ask questions. They’re demanding the full, unredacted data logs for all deceased patients.”

Professor Vance sat behind his desk, his face a grim mask. He swirled the amber liquid in his crystal glass, the ice clinking softly. He had built a forty-year career on a reputation of unimpeachable integrity. Now, it was all threatening to unravel because of one project. His project. His legacy.

“The data is… problematic,” Vance said, his voice a low rumble. He avoided Liam’s frantic gaze, staring instead at the report. “The correlation between sustained dosage and organ failure is becoming statistically significant. It’s no longer something we can dismiss as an anomaly.”

“So what do we do?” Liam demanded. “Do we pause the trial? Pull the plug? If we do that, we have nothing for Geneva. All of this—all of it will be for nothing.”

Vance took a slow sip of his scotch. He was at a precipice. On one side was professional ethics, safety, and a quiet, ignominious end to his grandest ambition. On the other was a terrible risk, but the potential for a Nobel-worthy breakthrough, for his name to be etched into the annals of medicine.

He had never been a man who chose the quiet path.

“We don’t pull the plug,” he said finally, his voice hard. “We manage the narrative. Patient 11, what were his comorbidities?”

“Advanced cirrhosis from a history of alcoholism,” Liam answered, confused. “It was in his file, but it was stable before treatment began.”

“It’s not stable anymore,” Vance declared, a new, ruthless certainty in his eyes. He leaned forward, tapping the report. “His pre-existing condition was exacerbated by the aggressive nature of his cancer. The d**g revealed an underlying weakness; it did not create it. That’s our official position.”

Liam stopped pacing. He understood. “You’re saying we falsify the primary cause. We re-code the data.”

“I’m saying we provide the correct medical interpretation,” Vance corrected him, his voice smooth as silk. He stood up and walked over to the lab’s server interface on a side console. “We are the experts here. It is our job to interpret the data, not to just blindly present it. We will clean the logs. Remove the outlier readings that are clouding the overall positive results. We will present a clear, compelling case for the d**g’s efficacy.”

He was talking about scientific fraud on a scale that could land them in federal prison. He was talking about sacrificing patients for prestige.

Liam stared at his mentor, a flicker of his old conscience warring with the ravenous hunger of his ambition. He saw Chloe’s expectant face, the diamond ring on her finger. He saw the stage in Geneva, the applause, the future he had killed his integrity to secure.

The war was over in an instant.

“Show me how,” Liam said, his voice barely a whisper.

For the next four hours, the two men worked in silence, meticulously altering the digital record of a dead man’s final days. They deleted enzyme readings, modified timestamps, and inserted fabricated notes about the patient’s “rapidly deteriorating underlying condition.” They sculpted a lie out of the truth, burying the victims of their ambition under a mountain of corrupted data.

When they were finished, the report was a work of fiction, but it was a believable one. Genesis-X was once again a miracle d**g.

Vance shut down the terminal and poured them both a drink. “There,” he said, handing a glass to Liam. “The crisis is averted. Now, get your presentation for Geneva ready. It needs to be flawless.”

Liam took the glass, his hand trembling slightly. He looked at the man he had once idolized, now his co-conspirator. They had crossed a line from which there was no return.

“They will believe us?” Liam asked, needing reassurance.

Vance smiled, a cold, thin-lipped expression. “My boy,” he said. “In our world, they don’t believe the data. They believe the man who presents it.”

Back in my silent, sterile lab at Apex, an alert pinged on my monitor. The data log for Patient 11 had been modified. I ran a comparison algorithm. The original file, scraped and saved by Med-Track just hours before, appeared on the left side of my screen. The newly altered file appeared on the right.

It was like looking at a photograph and its doctored twin. The changes were subtle, expert, and utterly damning.

A cold smile touched my lips. They had done it. They had taken the bait and sealed their own fates. They weren't just thieves anymore. They were killers, and now they were fools, leaving a digital trail of breadcrumbs leading directly to their crime.

Anya walked in, holding a tablet. “The preliminary speaker schedule for the Geneva summit was just released,” she said. “They’ve given them the closing keynote. The most prestigious spot of the entire conference.”

“Of course, they did,” I said, not taking my eyes off the two data files on my screen.

“Elara, this is their peak,” Anya said softly. “They will be on top of the world. Are you sure you can handle seeing that?”

I finally turned to look at her, my eyes clear and devoid of doubt. “It’s what I’m counting on.”

I thought of Liam’s smug, triumphant face. I thought of Professor Vance and his unshakeable arrogance. I saw them on that stage, accepting the world’s adulation for a miracle built on lies and death.

“Let them have their moment,” I said. “Let them fly. The higher they get, the further they have to fall.”